Treating residual cardiovascular risk: will lipoprotein-associated phospholipase A2 inhibition live up to its promise?
- PMID: 18436115
- DOI: 10.1016/j.jacc.2008.02.025
Treating residual cardiovascular risk: will lipoprotein-associated phospholipase A2 inhibition live up to its promise?
Comment on
-
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41. doi: 10.1016/j.jacc.2007.11.079. J Am Coll Cardiol. 2008. PMID: 18436114 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
